BioNTech kündigt Übernahme von InstaDeep an, um Vorreiterrolle auf dem Gebiet KI-basierter Arzneimittelforschung, -design und -entwicklung zu stärken
January 10, 2023 07:15 ET
|
BioNTech SE
Geplante Übernahme ermöglicht den Aufbau vollständig integrierter, unternehmensweiter Kapazitäten zur Erforschung, Konzeption und Entwicklung von Immuntherapien der nächsten Generation im großen...
BioNTech kündigt strategische Partnerschaft mit der Regierung des Vereinigten Königreichs an, um bis 2030 bis zu 10.000 Patientinnen und Patienten mit personalisierten mRNA-Krebsimmuntherapien zu behandeln
January 05, 2023 19:01 ET
|
BioNTech SE
Die mehrjährige Vereinbarung fokussiert sich auf drei strategische Bereiche: Krebsimmuntherapien, Impfstoffe gegen Infektionskrankheiten und weitere Expansion von BioNTech im Vereinigten...
BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030
January 05, 2023 19:01 ET
|
BioNTech SE
Multi-year collaboration focuses on three strategic pillars: cancer immunotherapies, infectious disease vaccines, and expansion of BioNTech’s footprint in the UKBioNTech aims to design and roll out...
BiondVax Announces Closing of $8 Million Underwritten Public Offering
December 20, 2022 12:42 ET
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)(“Company”), a biotechnology company, which focuses on developing, manufacturing, and...
Infectious Disease Diagnostics Market Size & Share to Surpass $ 41,291.40 Mn by 2028 | Vantage Market Research
December 16, 2022 03:41 ET
|
Vantage Market Research
WASHINGTON, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research analyses that the Global Infectious Disease Diagnostics Market is expected to reach a value of $ 41,291.40 Million by 2028, at a...
Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board
December 06, 2022 07:30 ET
|
BiondVax Pharmaceuticals Ltd.
Jerusalem, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing...
Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results
December 05, 2022 06:30 ET
|
Veru Inc.
U.S. FDA reviewing EUA application for sabizabulin to treat hospitalized COVID-19 patients at high risk for ARDS European Medicines Agency’s (EMA) Emergency Task Force reviewing sabizabulin for...
POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19
November 30, 2022 15:01 ET
|
POP Biotechnologies
BUFFALO, N.Y., Nov. 30, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the publication of an interim analysis of the Phase 2...
PDS Biotech Executives to Present an Overview of Oncology and Infectious Disease Programs at the World Vaccine & Immunotherapy Congress
November 21, 2022 08:00 ET
|
PDS Biotechnology Corporation
Chief Medical Officer, Dr. Lauren V. Wood, to present on the development of targeted immunotherapies for solid tumors based on the Versamune® platform Dr. Siva Gandhapudi, Director of...
BiondVax Announces Plan to Implement ADS Ratio Change
November 10, 2022 16:00 ET
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and...